BioCentury | Jul 25, 2013
Cover Story

MPS IIIA: gene therapy for brain and body

Less than a year after reporting preclinical proof of concept for a systemically delivered mucopolysaccharidosis IIIA gene therapy, researchers at the Autonomous University of Barcelona have shown that intracerebral delivery can substantially improve efficacy in...
BioCentury | Jun 29, 2009
Emerging Company Profile

Phrixus: Healing Broken Hearts

...disease. In the early 2000s, Valentis Inc. reached Phase IIb to treat peripheral arterial disease (PAD). Valentis...
BioCentury | Jan 8, 2009
Cover Story

Taking the inflammation out of epilepsy

...cardiovascular space. In 2004, Deltavasc, a cationic lipid for delivery of the DEL1 gene from Valentis Inc....
BioCentury | Aug 25, 2008
Company News

Lipoxen management update

...U.K. Business: Drug delivery Hired: Ajay Agrawal, founder of polyMASC Pharmaceuticals plc (now part of Valentis Inc....
BioCentury | Aug 6, 2007
Company News

Valentis genitourinary, cardiovascular news

...ticker to URGP. VLTS reverse-merged with Urigen N.A. Inc. last month (see BioCentury, July 23). Valentis Inc....
BioCentury | Jul 23, 2007
Company News

Urigen N.A. Inc., Valentis deal

...their previously announced reverse-merger and will form Urigen Pharmaceuticals Inc. (see BioCentury, Oct. 9, 2006). Valentis'...
...will remain VLTS until its name change is complete. Urigen N.A. Inc. , Burlingame, Calif. Valentis Inc....
BioCentury | Nov 6, 2006
Company News

Valentis, Vical deal

...portfolio of issued and pending patents covering undisclosed manufacturing processes. Further terms were not disclosed. Valentis Inc....
BioCentury | Nov 6, 2006
Clinical News

U101: Phase IIb data

...will incorporate protocol changes related to patient selection in subsequent trials. Urigen is merging with Valentis Inc....
BioCentury | Oct 31, 2006
Clinical News

Urigen's U101 misses Phase IIb endpoint

...patients. U101 is an intravesical formulation of heparin and alkalinized lidocaine. Urigen is merging with Valentis...
BioCentury | Oct 23, 2006
Company News

Inovio Biomedical Corp., Valentis deal

...Urigen Holdings (Vancouver, B.C.) (see BioCentury, Oct. 9). Inovio Biomedical Corp. (INO), San Diego, Calif. Valentis Inc....
Items per page:
1 - 10 of 200
BioCentury | Jul 25, 2013
Cover Story

MPS IIIA: gene therapy for brain and body

Less than a year after reporting preclinical proof of concept for a systemically delivered mucopolysaccharidosis IIIA gene therapy, researchers at the Autonomous University of Barcelona have shown that intracerebral delivery can substantially improve efficacy in...
BioCentury | Jun 29, 2009
Emerging Company Profile

Phrixus: Healing Broken Hearts

...disease. In the early 2000s, Valentis Inc. reached Phase IIb to treat peripheral arterial disease (PAD). Valentis...
BioCentury | Jan 8, 2009
Cover Story

Taking the inflammation out of epilepsy

...cardiovascular space. In 2004, Deltavasc, a cationic lipid for delivery of the DEL1 gene from Valentis Inc....
BioCentury | Aug 25, 2008
Company News

Lipoxen management update

...U.K. Business: Drug delivery Hired: Ajay Agrawal, founder of polyMASC Pharmaceuticals plc (now part of Valentis Inc....
BioCentury | Aug 6, 2007
Company News

Valentis genitourinary, cardiovascular news

...ticker to URGP. VLTS reverse-merged with Urigen N.A. Inc. last month (see BioCentury, July 23). Valentis Inc....
BioCentury | Jul 23, 2007
Company News

Urigen N.A. Inc., Valentis deal

...their previously announced reverse-merger and will form Urigen Pharmaceuticals Inc. (see BioCentury, Oct. 9, 2006). Valentis'...
...will remain VLTS until its name change is complete. Urigen N.A. Inc. , Burlingame, Calif. Valentis Inc....
BioCentury | Nov 6, 2006
Company News

Valentis, Vical deal

...portfolio of issued and pending patents covering undisclosed manufacturing processes. Further terms were not disclosed. Valentis Inc....
BioCentury | Nov 6, 2006
Clinical News

U101: Phase IIb data

...will incorporate protocol changes related to patient selection in subsequent trials. Urigen is merging with Valentis Inc....
BioCentury | Oct 31, 2006
Clinical News

Urigen's U101 misses Phase IIb endpoint

...patients. U101 is an intravesical formulation of heparin and alkalinized lidocaine. Urigen is merging with Valentis...
BioCentury | Oct 23, 2006
Company News

Inovio Biomedical Corp., Valentis deal

...Urigen Holdings (Vancouver, B.C.) (see BioCentury, Oct. 9). Inovio Biomedical Corp. (INO), San Diego, Calif. Valentis Inc....
Items per page:
1 - 10 of 200